MX364040B - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). - Google Patents
Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).Info
- Publication number
- MX364040B MX364040B MX2016014775A MX2016014775A MX364040B MX 364040 B MX364040 B MX 364040B MX 2016014775 A MX2016014775 A MX 2016014775A MX 2016014775 A MX2016014775 A MX 2016014775A MX 364040 B MX364040 B MX 364040B
- Authority
- MX
- Mexico
- Prior art keywords
- nafld
- nash
- reversal
- extended
- treatment
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003073 pirfenidone Drugs 0.000 title abstract 2
- 208000004930 Fatty Liver Diseases 0.000 title 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 230000002440 hepatic effect Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 210000002824 peroxisome Anatomy 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 abstract 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 abstract 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 abstract 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con el uso de una composición farmacéutica en forma de comprimidos de liberación prolongada que contienen pirfenidona para el tratamiento de NAFLD/NASH y la fibrosis hepática avanzada, mediante la disminución sérica de colesterol y triglicéridos, así como la disminución del contenido del acúmulo de grasa hepática, tanto en la forma de macroesteatosis como microesteatosis. Adicionalmente, su uso como agonista para PPARgamma (peroxisoma proliferación receptor activado gamma), PPARalfa (peroxisoma proliferación receptor activado alfa), LXR y CPT1, moléculas clave en el metabolismo de degradación de las grasas e inflamación hepáticas. Asimismo, otro uso adicional consiste en la inducción de la disminución de la expresión del gen maestro NFkB, factor transcripcional inductor del proceso inflamatorio hepático. Todos estos eventos resultan en la reversión de NAFLD/NASH y la fibrosis hepática avanzada.
Priority Applications (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| JOP/2019/0102A JOP20190102A1 (ar) | 2016-11-11 | 2017-06-16 | استخدام صيدلي لتركيب له إطلاق ممتد يحتوي على بيرفنيدون من أجل علاج والتعافي من التهاب الكبد الدهني البشري ((داء الكبد الدهني غير الكحولي nafld)/التهاب الكبد الدهني غير الكحولي nash)) |
| US16/348,189 US20190262325A1 (en) | 2016-11-11 | 2017-11-09 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| RU2019116422A RU2019116422A (ru) | 2016-11-11 | 2017-11-09 | Фармацевтическое применение композиции пролонгированного действия, содержащей пирфенидон, для лечения и обращения течения стеатогепатита человека (nafld/nash) |
| CA3043300A CA3043300A1 (en) | 2016-11-11 | 2017-11-09 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| KR1020247015017A KR20240065330A (ko) | 2016-11-11 | 2017-11-09 | 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 |
| UY0001037478A UY37478A (es) | 2016-11-11 | 2017-11-09 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) |
| AU2017358367A AU2017358367B2 (en) | 2016-11-11 | 2017-11-09 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) |
| MA45754A MA45754A1 (fr) | 2016-11-11 | 2017-11-09 | Utilisation pharmaceutique d'une composition à base de pirfénidone à libération prolongée (pfd-lp) pour la réversion de la stéatose hépatique humaine (nafld/nash) |
| PE2019000946A PE20191149A1 (es) | 2016-11-11 | 2017-11-09 | Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash) |
| KR1020197014274A KR20190084056A (ko) | 2016-11-11 | 2017-11-09 | 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 |
| EP17840578.3A EP3539537A1 (en) | 2016-11-11 | 2017-11-09 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| CN201780076430.3A CN110248646A (zh) | 2016-11-11 | 2017-11-09 | 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途 |
| JP2019547064A JP2019535822A (ja) | 2016-11-11 | 2017-11-09 | ヒト脂肪性肝炎（ｎａｆｌｄ／ｎａｓｈ）の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
| CN202211265065.XA CN115969802A (zh) | 2016-11-11 | 2017-11-09 | 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途 |
| PCT/MX2017/000129 WO2018088886A1 (es) | 2016-11-11 | 2017-11-09 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) |
| ARP170103142A AR110057A1 (es) | 2016-11-11 | 2017-11-10 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) |
| IL266519A IL266519A (en) | 2016-11-11 | 2019-05-08 | Pharmaceutical use of a sustained-release preparation containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) |
| ECSENADI201931851A ECSP19031851A (es) | 2016-11-11 | 2019-05-08 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) |
| CL2019001280A CL2019001280A1 (es) | 2016-11-11 | 2019-05-09 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| PH12019501047A PH12019501047A1 (en) | 2016-11-11 | 2019-05-10 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| CONC2019/0004799A CO2019004799A2 (es) | 2016-11-11 | 2019-05-10 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) |
| ZA2019/03012A ZA201903012B (en) | 2016-11-11 | 2019-05-14 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| JP2022152261A JP2022173344A (ja) | 2016-11-11 | 2022-09-26 | ヒト脂肪性肝炎（ｎａｆｌｄ／ｎａｓｈ）の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
| US18/051,937 US20230181550A1 (en) | 2016-11-11 | 2022-11-02 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
| AU2024200737A AU2024200737A1 (en) | 2016-11-11 | 2024-02-07 | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014775A MX2016014775A (es) | 2018-05-10 |
| MX364040B true MX364040B (es) | 2019-04-11 |
Family
ID=61193005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20190262325A1 (es) |
| EP (1) | EP3539537A1 (es) |
| JP (2) | JP2019535822A (es) |
| KR (2) | KR20240065330A (es) |
| CN (2) | CN115969802A (es) |
| AR (1) | AR110057A1 (es) |
| AU (2) | AU2017358367B2 (es) |
| CA (1) | CA3043300A1 (es) |
| CL (1) | CL2019001280A1 (es) |
| CO (1) | CO2019004799A2 (es) |
| EC (1) | ECSP19031851A (es) |
| IL (1) | IL266519A (es) |
| JO (1) | JOP20190102A1 (es) |
| MA (1) | MA45754A1 (es) |
| MX (1) | MX364040B (es) |
| PE (1) | PE20191149A1 (es) |
| PH (1) | PH12019501047A1 (es) |
| RU (1) | RU2019116422A (es) |
| UY (1) | UY37478A (es) |
| WO (1) | WO2018088886A1 (es) |
| ZA (1) | ZA201903012B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| EP3716975A4 (en) * | 2017-11-28 | 2022-01-12 | Eiger Biopharmaceuticals, Inc. | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| US20230391892A1 (en) * | 2020-10-23 | 2023-12-07 | Hq Han | Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof |
| CN117007806A (zh) * | 2023-09-21 | 2023-11-07 | 中国人民解放军军事科学院军事医学研究院 | 靶向肝巨噬细胞内lxr用于控制慢乙肝进展 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4077320B2 (ja) * | 2001-01-29 | 2008-04-16 | 塩野義製薬株式会社 | ５−メチル−１−フェニル−２−（１ｈ）−ピリドンを有効成分として含有する医薬製剤 |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| CN100542532C (zh) * | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
| CA2741954A1 (en) * | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN102488660A (zh) * | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
| CN103550242B (zh) * | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
-
2016
- 2016-11-11 MX MX2016014775A patent/MX364040B/es active IP Right Grant
-
2017
- 2017-06-16 JO JOP/2019/0102A patent/JOP20190102A1/ar unknown
- 2017-11-09 US US16/348,189 patent/US20190262325A1/en not_active Abandoned
- 2017-11-09 EP EP17840578.3A patent/EP3539537A1/en active Pending
- 2017-11-09 JP JP2019547064A patent/JP2019535822A/ja active Pending
- 2017-11-09 CN CN202211265065.XA patent/CN115969802A/zh active Pending
- 2017-11-09 KR KR1020247015017A patent/KR20240065330A/ko not_active Application Discontinuation
- 2017-11-09 WO PCT/MX2017/000129 patent/WO2018088886A1/es active Application Filing
- 2017-11-09 PE PE2019000946A patent/PE20191149A1/es unknown
- 2017-11-09 KR KR1020197014274A patent/KR20190084056A/ko not_active Application Discontinuation
- 2017-11-09 MA MA45754A patent/MA45754A1/fr unknown
- 2017-11-09 RU RU2019116422A patent/RU2019116422A/ru unknown
- 2017-11-09 AU AU2017358367A patent/AU2017358367B2/en active Active
- 2017-11-09 UY UY0001037478A patent/UY37478A/es not_active Application Discontinuation
- 2017-11-09 CN CN201780076430.3A patent/CN110248646A/zh active Pending
- 2017-11-09 CA CA3043300A patent/CA3043300A1/en active Pending
- 2017-11-10 AR ARP170103142A patent/AR110057A1/es unknown
-
2019
- 2019-05-08 EC ECSENADI201931851A patent/ECSP19031851A/es unknown
- 2019-05-08 IL IL266519A patent/IL266519A/en unknown
- 2019-05-09 CL CL2019001280A patent/CL2019001280A1/es unknown
- 2019-05-10 PH PH12019501047A patent/PH12019501047A1/en unknown
- 2019-05-10 CO CONC2019/0004799A patent/CO2019004799A2/es unknown
- 2019-05-14 ZA ZA2019/03012A patent/ZA201903012B/en unknown
-
2022
- 2022-09-26 JP JP2022152261A patent/JP2022173344A/ja active Pending
- 2022-11-02 US US18/051,937 patent/US20230181550A1/en not_active Abandoned
-
2024
- 2024-02-07 AU AU2024200737A patent/AU2024200737A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535822A (ja) | 2019-12-12 |
| EP3539537A1 (en) | 2019-09-18 |
| RU2019116422A (ru) | 2020-12-11 |
| KR20240065330A (ko) | 2024-05-14 |
| CN110248646A (zh) | 2019-09-17 |
| UY37478A (es) | 2018-05-31 |
| RU2019116422A3 (es) | 2021-04-09 |
| WO2018088886A1 (es) | 2018-05-17 |
| AR110057A1 (es) | 2019-02-20 |
| CA3043300A1 (en) | 2018-05-17 |
| MX2016014775A (es) | 2018-05-10 |
| ZA201903012B (en) | 2020-09-30 |
| CN115969802A (zh) | 2023-04-18 |
| CL2019001280A1 (es) | 2019-07-19 |
| AU2017358367A1 (en) | 2019-05-30 |
| AU2024200737A1 (en) | 2024-02-22 |
| JOP20190102A1 (ar) | 2019-05-06 |
| AU2017358367B2 (en) | 2023-11-09 |
| US20190262325A1 (en) | 2019-08-29 |
| ECSP19031851A (es) | 2019-06-30 |
| PE20191149A1 (es) | 2019-09-02 |
| JP2022173344A (ja) | 2022-11-18 |
| CO2019004799A2 (es) | 2019-07-31 |
| US20230181550A1 (en) | 2023-06-15 |
| KR20190084056A (ko) | 2019-07-15 |
| MA45754A1 (fr) | 2019-12-31 |
| IL266519A (en) | 2019-07-31 |
| PH12019501047A1 (en) | 2019-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501047A1 (en) | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) | |
| MX2020006273A (es) | Compuestos policiclicos como inhibidores alostericos de shp2. | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| IN2015DN00376A (es) | ||
| PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| Adler et al. | Glucocorticoid-induced osteoporosis | |
| MY188344A (en) | Extract formulations of rhodamnia cinerea and uses thereof | |
| HK1256909A1 (zh) | Glp-1和其在用於治療代謝疾病的組合物中的用途 | |
| EP3661600A4 (en) | FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME | |
| IL272457A (en) | GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MY175764A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| PH12016501548A1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
| EP3316874A4 (en) | TOPICAL AND INJECTABLE RESIQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC GUM DISEASES | |
| MA40590A (fr) | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| MX2018004489A (es) | Extracto de agavaceae que comprende saponinas esteroidales y su uso para tratar y/o prevenir patologías relacionadas con desórdenes metabólicos. | |
| EP3677272A4 (en) | APPLICATION OF ALISTIPES SHAHII IN THE PREPARATION OF A COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF DISEASES ASSOCIATED WITH LIPID METABOLISM | |
| SG11202102199VA (en) | Traditional chinese medicine composition for treating metabolic syndrome and preparations thereof | |
| WO2017189717A8 (en) | METHOD FOR MAINTAINING IRON HOMESTASIA USING SHOGAOLS | |
| EP3868217A4 (en) | LIPID MICRONUTRIENT COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES | |
| Schmidt et al. | Stress-induced local inflammation correlates with an increase in inflammatory myeloid cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |